Sofie H Mooij1, Olivia Landén2, Fiona R M van der Klis3, Marianne A B van der Sande4, Hester E de Melker3, Roel A Coutinho4, Arne van Eeden5, Martijn S van Rooijen2, Chris J L M Meijer6, Maarten F Schim van der Loeff7. 1. Cluster of Infectious Diseases, Public Health Service of Amsterdam (GGD), Amsterdam, The Netherlands; Center for Infection and Immunity Amsterdam (CINIMA), Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: somooij@ggd.amsterdam.nl. 2. Cluster of Infectious Diseases, Public Health Service of Amsterdam (GGD), Amsterdam, The Netherlands. 3. Centre for Infectious Disease Control, National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM), Bilthoven, The Netherlands. 4. Centre for Infectious Disease Control, National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM), Bilthoven, The Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 5. Department of Internal Medicine, Jan van Goyen Medical Center, Amsterdam, The Netherlands. 6. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. 7. Cluster of Infectious Diseases, Public Health Service of Amsterdam (GGD), Amsterdam, The Netherlands; Center for Infection and Immunity Amsterdam (CINIMA), Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
OBJECTIVES: To assess whether HPV serum antibodies detected after natural infection protect against subsequent anal or penile infection with the same HPV type in HIV-negative and HIV-infected men who have sex with men (MSM). METHODS: MSM aged ≥18 years were recruited in Amsterdam, the Netherlands (2010-2011), and followed-up semi-annually. Antibodies against 7 high-risk HPV types in baseline serum samples were tested using a multiplex immunoassay; baseline, 6-, and 12-month anal and penile samples were tested for HPV DNA and genotyped using the SPF10-PCR DEIA/LiPA25 system (version 1). Statistical analyses were performed using the Wei-Lin-Weissfeld method. RESULTS: 719 MSM (median age 40 years; IQR 35-48) with baseline and follow-up data were included in these analyses; 287 (40%) were HIV-infected. HPV seropositivity at baseline was not significantly associated with subsequent type-specific HPV infection at 6 or 12 months in multivariable analyses (for anal infection adjusted hazard ratio (aHR) 1.2; 95% CI 0.9-1.6; for penile infection aHR 0.8; 95% CI 0.6-1.2). High antibody concentrations showed no protective effect against subsequent infection either. CONCLUSIONS: In a population of highly sexually active, adult MSM, naturally induced HPV antibodies may not protect MSM against subsequent anal or penile HPV infection within one year.
OBJECTIVES: To assess whether HPV serum antibodies detected after natural infection protect against subsequent anal or penile infection with the same HPV type in HIV-negative and HIV-infectedmen who have sex with men (MSM). METHODS: MSM aged ≥18 years were recruited in Amsterdam, the Netherlands (2010-2011), and followed-up semi-annually. Antibodies against 7 high-risk HPV types in baseline serum samples were tested using a multiplex immunoassay; baseline, 6-, and 12-month anal and penile samples were tested for HPV DNA and genotyped using the SPF10-PCR DEIA/LiPA25 system (version 1). Statistical analyses were performed using the Wei-Lin-Weissfeld method. RESULTS: 719 MSM (median age 40 years; IQR 35-48) with baseline and follow-up data were included in these analyses; 287 (40%) were HIV-infected. HPV seropositivity at baseline was not significantly associated with subsequent type-specific HPV infection at 6 or 12 months in multivariable analyses (for anal infection adjusted hazard ratio (aHR) 1.2; 95% CI 0.9-1.6; for penile infection aHR 0.8; 95% CI 0.6-1.2). High antibody concentrations showed no protective effect against subsequent infection either. CONCLUSIONS: In a population of highly sexually active, adult MSM, naturally induced HPV antibodies may not protect MSM against subsequent anal or penile HPV infection within one year.
Authors: Daniel C Beachler; Raphael Viscidi; Elizabeth A Sugar; Howard Minkoff; Howard D Strickler; Ross D Cranston; Dorothy J Wiley; Lisa P Jacobson; Kathleen M Weber; Joseph B Margolick; Susheel Reddy; Maura L Gillison; Gypsyamber D'Souza Journal: Sex Transm Dis Date: 2015-02 Impact factor: 2.830
Authors: Shitaldas J Pamnani; Staci L Sudenga; Raphael Viscidi; Dana E Rollison; B Nelson Torres; Donna J Ingles; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Jorge Salmeron; Manuel Quiterio; Yangxin Huang; Amy Borenstein; Anna R Giuliano Journal: Cancer Res Date: 2016-08-17 Impact factor: 12.701
Authors: Christine M Pierce Campbell; Raphael P Viscidi; B Nelson Torres; Hui-Yi Lin; William Fulp; Martha Abrahamsen; Eduardo Lazcano-Ponce; Luisa L Villa; Aimée R Kreimer; Anna R Giuliano Journal: J Infect Dis Date: 2016-02-29 Impact factor: 5.226
Authors: Elissa Meites; Pamina M Gorbach; Beau Gratzer; Gitika Panicker; Martin Steinau; Tom Collins; Adam Parrish; Cody Randel; Mark McGrath; Steven Carrasco; Janell Moore; Akbar Zaidi; Jim Braxton; Peter R Kerndt; Elizabeth R Unger; Richard A Crosby; Lauri E Markowitz Journal: J Infect Dis Date: 2016-06-13 Impact factor: 5.226
Authors: Daniel C Beachler; Ligia A Pinto; Troy J Kemp; Alan G Nyitray; Allan Hildesheim; Raphael Viscidi; John Schussler; Aimée R Kreimer; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-02-23 Impact factor: 4.254
Authors: Anna R Giuliano; Raphael Viscidi; B Nelson Torres; Donna J Ingles; Staci L Sudenga; Luisa L Villa; Maria Luiza Baggio; Martha Abrahamsen; Manuel Quiterio; Jorge Salmeron; Eduardo Lazcano-Ponce Journal: Papillomavirus Res Date: 2015-12-01